189 results about "Reactive intermediate" patented technology

The invention discloses a method for preparing phosphotungstic heteropoly acid with a Keggin structure. The method comprises the following steps of: (1) contacting a tungstate solution and an inorganic acid solution; (2) transferring the solution to a high-pressure reaction kettle, and activating at high temperature under high pressure to obtain an active intermediate; (3) contacting the obtained substance and phosphoric acid to obtain a phosphotungstic acid solution; and (4) adding an inorganic salt precipitator into the phosphotungstic acid solution, precipitating phosphotungstic acid by salting-out and crystallization, filtering, purifying and drying to obtain the Keggin phosphotungstic heteropoly acid. By the method, a process flow is simple, the yield of the heteropoly acid is high, and the preparation cost is reduced obviously; high-concentration strong acid in the conventional method is not used in the preparation process, so that the corrosivity to equipment is reduced greatly; and an inflammable low-boiling point organic extractant is not used, and the safety of preparation is improved greatly.

The invention discloses an Apixaban preparation method. The Apixaban preparation method comprises that 1, an intermediate I and an intermediate II undergo a [3+2] cyclization addition reaction under the alkali action to produce a compound B, and the compound B undergoes a morpholine ring removal reaction under the acid condition to produce a compound C, 2, the compound C is reduced by iron powder to form a corresponding amino compound D, 3, the amino compound D and 5-chlorovaleryl chloride undergo an amidation reaction under the triethylamine action to produce a compound E, 4, the compound E undergoes a cyclization reaction under the strong base action to produce a compound F, 5, the compound F undergoes a hydrolysis reaction under the strong base action to produce a corresponding carboxyl compound G, and 6, the carboxyl compound G and CDI undergo a reaction to produce an active intermediate H and the active intermediate H and ammonia water undergo an aminolysis reaction to produce the desired compound A. The Apixaban preparation method has simple processes, does not need strict reaction conditions, has low equipment requirements, has high reaction yield, utilizes stable intermediates thereby solving intermediate storage problems, and effectively improves product purity.

The present invention relates to a composite electrode material having a carbon base material and iron oxide particles mainly containing Fe₃O₄ and being supported on the carbon base material and the particles have a D₉₀ of 50 nm or less. In the composite electrode material, since the particle size of the iron oxide particles mainly containing Fe₃O₄ serving as an active material is small, the electron conductivity of the composite electrode material is not considerably reduced even when being covered with a Fe(OH)₂ layer as a reactive intermediate for an electrode reaction. Thus, when the composite electrode material is used, an iron negative electrode having sufficient electron conductivity and charge-discharge cycle characteristics is provided. A negative electrode including the composite electrode material is favorably used as a negative electrode for a metal-air battery.

A method of modifying a particle that includes reacting a reactive compound having an X—[Y]_n reactive group with a secondary compound N—S-ZM to form a substituted reactive intermediate [Y]_a—X—(N—S-ZM)_b, and reacting the particle with the substituted reactive intermediate [Y]_a—X—(N—S-ZM)_b to attach the substituted reactive intermediate to the surface of the particle to form a surface modified particle. The particle may comprise at least one of a dye particle, an inorganic pigment particle, an additive, or a combination thereof. X may be a sulfonyl, phosphoryl, or 1,3,5-triazinyl group. Y may be a halogen leaving group. N may be a nucleophilic group. S may be an organic group. ZM may be an ionizable end group. Also, n is an integer between 1 and 3, b is an integer between 1 and 3, and a=n−b. When n is equal to or greater than b, and wherein if b is 2 or 3, each N—S-ZM can be the same or different.

A reactor for forming a reactive intermediate from a precursor for the deposition of a low dielectric constant polymer film via transport polymerization is disclosed. The reactor includes an inlet for admitting a flow of the precursor into the reactor, an interior for converting the precursor to the reactive intermediate, an outlet for admitting a flow of the reactive intermediate out of the interior, and at least one of an energy source and an oxidant source associated with the outlet for decomposing residues in the outlet.

The invention discloses a galactosylated chitosan scaffold material for a bioartificial liver, which is a galactosylated chitosan biological material with a three-dimensional porous structure which is cross-linked by an oxidized sodium alginate biological crosslinking agent. Its main preparation process: chitosan and lactobionic acid are dissolved in tetramethylethylenediamine/hydrochloric acid mixed solution in an equimolar ratio, and active intermediates are added to activate the reaction to prepare galactosylated chitosan; galactosylated chitosan is dissolved in Acetic acid solution and oxidized sodium alginate are dissolved in ultrapure water, and the two solutions are mixed in a certain proportion to carry out cross-linking reaction. After the reaction is completed, pour it into a mold for molding, freeze-dry to obtain a scaffold material, and then immerse it in sodium hydroxide- The residual acetic acid was removed by ethanol aqueous solution, and then washed by ethanol aqueous solution and freeze-dried twice to obtain the galactosylated chitosan scaffold material cross-linked by oxidized sodium alginate. The galactosylated chitosan scaffold material of the invention has a pore size suitable for the growth of liver cells and good biocompatibility.

A bio compatible free radical suspension, comprising of oxygen and electronically modified reaction intermediates, where a fluorocarbon is used as an inert medium for stabilization of reaction intermediates. A stabilized bio compatible electronically modified derivative suspension is produced by the subjecting a fluorocarbon to certain stressors, such as oxidizing agents, reactive intermediates, physiological gases, benzo-γ-pyrone derivatives, ultrasonic-cavitation, electric fields, magnetic fields, UV radiation, active metal catalyst, surfactant reactants, buffers, electrolytes, glucose, glucose derivatives, for the purpose of inducing a cascading immune response.

The invention discloses a method for preparing Dawson heteropolyphosphatotungstate. The method comprises the following steps: (1) enabling a tungstate solution to come into contact with an inorganic acid solution, so as to obtain a reactive intermediate; (2) continuously enabling the solution to come into contact with a phosphoric acid solution, so as to obtain a phosphotungstic acid solution; (3) transferring the phosphotungstic acid solution to a high-pressure reactor, and carrying out high-temperature and high-pressure reaction; (4) adding an inorganic salt precipitant to the obtained phosphotungstic acid solution, carrying out salting-out crystallization to obtain phosphotungstate, filtering, purifying and drying, so as to obtain the Dawson heteropolyphosphatotungstate. Compared with the prior art, the method is simple in technological process, short in reaction cycle, high in yield and product purity, and low in cost; meanwhile, strong acid acidification and diethyl ether extraction used in the traditional method are avoided; the safety of the preparation process is greatly improved.

The invention discloses a preparation method for a photoinitiator bis(2,4,6-trimethylbenzoyl)phenylphosphine oxide. The preparation method comprises the synthesis steps: under the protection of inert gas, carrying out a reaction of aluminium trichloride or tin tetrachloride and trimethylsilane in the temperature range of 0-100 DEG C to obtain aluminium dichloride ions, and rapidly acting with dichlorophenyl phosphine in the reaction system, to obtain a bis(aluminium trichloride or tin tetrachloride)phosphine salt intermediate; then carrying out a reaction of the intermediate and 2,4,6-trimethyl benzoyl chloride, to obtain bis(2,4,6-trimethylbenzoyl)phenyl phosphine; and under the condition of the temperature of 20-50 DEG C, oxidizing by nitrogen dioxide, to obtain the target product. The method avoids use of a dangerous active metal potassium or sodium, and adopts aluminium trichloride or tin tetrachloride with relatively low price and trimethylsilane for on-site generation of the active intermediate to achieve the reaction. The method has the characteristics of low preparation cost, simple and safe operation process, easy control of the reaction process, high product yield, good purity, easy realization of mass production and the like.

The invention relates to application of a compound with a flavone skeleton structure as a Parkinsonism treating medicine. The compound with a flavone skeleton structure is an inhibitor for the catechol methylation transferase; and the compound specifically comprises radix scutellariae, scutellarein and structure derivatives of radix scutellariae and scutellarein, and can be used as a synergist of the Parkinsonism treating medicine levodopa. In-vitro activity test indicates that IC50 of the compound in inhibiting catechol methylation transferase can reach nanomole level, wherein the COMT(Catechol O Methyl Transferase) inhibition activity of scutellarein and the derivatives of scutellarein is superior to that of medicine tolcapone on the market. The rat overall pharmacokinetic study shows that by the joint application of scutellarein and levodopa, the blood concentration of levodopa can be obviously increased. Moreover, the compound does not generate active intermediate through metabolism activation or form toxic adduct together with biological macromolecules, thus the hepatotoxicity and nephrotoxicity caused by metabolism activation are avoided, and the compound has good prospect of patent medicine.

A process for producing a substrate having an adhesive surface, which process comprises: (a) contacting the substrate with a carbene precursor, which carbene precursor is a compound of the following formula (1): whose substituent groups are SP defined herein, provided that when R is aryl or heteroaryl, said aryl or heteroaryl may be substituted by one, two, three, four or five groups, which groups are independently selected from various groups including -L_B-W_B; and (b) either: (i) when W_A or W_B comprises an adhesive functional group, generating a carbene reactive intermediate from the carbene precursor so that it reacts with the substrate to functionalise the surface, thereby yielding said substrate having an adhesive surface; or (ii) when W_A or W_B comprises a group which is a precursor of an adhesive functional group, generating a carbene reactive intermediate from the carbene precursor so that it reacts with the substrate to functionalise the surface, and (c) converting said group which is a precursor into an adhesive functional group thereby yielding said substrate having an adhesive surface. The invention further relates to carbene precursor compounds for use in the process, substrates produced by the process and to processes for preparing certain precursor compounds.

A laminating resin having low styrene content is provided. The resin includes a thermosetting resin and a reactive intermediate including a low molecular weight polyester oligomer endcapped with at least one (meth)acrylic acid, its ester or its anhydride thereof.

The invention relates to a medicine composition of myricetrin or/and myricetin aglycone thereof and levodopa or of levodopa and carbidopa and an application of myricetrin or/and myricetin aglycone thereof as a synergist in preparation of a medicine used for treating Parkinson. In vitro activity determination finds that IC50 of myricetrin and myricetin inhibiting catechol-O-methyltransferase (COMT) can be a micromole-nanomole scale. Rat overall pharmacokinetic study finds that blood concentration of levodopa can be increased after myricetrin and myricetin aglycone thereof and levodopa are used jointly; and myricetrin and myricetin aglycone thereof are high in safety, no obvious toxicity is produced to main visceral organ cells of a human body, and no active intermediate is produced by virtue of metabolism activation and further no damage done to organs such as liver and kidney is initiated, so that the myricetrin and myricetin aglycone thereof have a good application prospect in adjuvant therapy of Parkinson.

The invention relates to the technical field of coal catalytic gasification, in particular to a heavy tar and fine powder treatment method. Heavy tar and fine powder can be converted into a light-weight oil product, so that conditions are created for the clean and efficient utilization of coal. The embodiment of the invention provides the heavy tar and fine powder treatment method. The heavy tar and the fine powder respectively contain catalysts. The method comprises the following steps that activation treatment is performed on the heavy tar to obtain the heavy tar subjected to activation treatment; the activation treatment is performed on the fine powder to obtain the fine powder subjected to the activation treatment; wherein the heavy tar subjected to the activation treatment comprises a first active intermediate, and the fine powder subjected to the activation treatment comprises a second active intermediate; 2, the heavy tar subjected to the activation treatment and the fine powder subjected to the activation treatment are mixed; the mixture is introduced into a supercritical reactor; under the supercritical state of an organic solvent, the first active intermediate and the second active intermediate take a reaction to produce the light-weight oil product and ash slag.

The method of degrading Napolean green in waste water is to degrade Napolean green in waste water with ultraviolet ray of 185 nm wavelength. Waste water containing Napolean green in 10 mg/L is first fed into a water tank, and then the waste water is pumped into the 185 nm ultraviolet reactor in the flow rate of 0.14-0.70 L/min while the reacted waste water is pumped into the water tank circularly in the flow rate of 40-160 L/hr. Monitoring on the Napolean green concentration of the water sample from the water tank shows that the Napolean green degrading rate in 40 min reaches over 99 % and the waste water reaches the draining stardard. The 185 nm wavelength ultraviolet ray acts on water to produce homolytic reaction of water and produce hydrated electrons in high concentration as active intermediate. The present invention has high degrading effect, high degrading speed, low running cost, no secondary pollution and other advantages.